|
|
|
|
|
|
| Apexum receives FDA 510(k) clearance to market its Apexum Ablator device |
|
| May. 6, 2009 |
|
Apexum Ltd. has announced that it has been notified by the United States Food and Drug Administration that it has received 510(k) premarket notification clearance for the Apexum Ablator device.
The Apexum device is an endodontic tool for the removal of necrotic or inflamed tissue from the periapical region.
Apexum believes that the achievement of this significant milestone is an important step towards the commercialization of the Apexum device, and excepts to generate worldwide revenues through local distributors.
Apexum is an R&D company located in Or Yehuda, Israel, which develops and commercializes a family of proprietary miniature, minimally-invasive dental surgical tools, for the treatment of Periapical Lesions. |
|
|
|
|
